Original filing text · Part II

Item 1 — Legal Proceedings

Teva Pharmaceutical Industries Limited · 10-Q · Q2 FY2026 · Period ended Jun 30, 2026

This is the extracted source text from the SEC filing. Formatting may differ from the original document.

We are subject to various litigation and other legal proceedings. Information pertaining to legal proceedings can be found in “Item 1 Financial Statements—Note 10 Contingencies” and is incorporated by reference herein.